Leishmania species

Leishmania species are single-celled, parasitic protozoa in the family Trypanosomatidae, transmitted by sand flies and responsible for the infectious disease leishmaniasis, which manifests as cutaneous, mucocutaneous, or visceral forms[7][3][1]. These parasites exist primarily in two stages: the promastigote (flagellated, found in sand flies) and the amastigote (non-flagellated, intracellular, found in host macrophages)[3][1][9]. Their unique surface molecules, like lipophosphoglycan, play critical roles in immune modulation and survival by evading host immune responses[5]. Leishmania parasites are a major focus of therapeutic research, with drugs targeting essential metabolic pathways and unique parasite enzymes to avoid off-target effects on human cells[6][8]. However, the term "Leishmania species" itself is too broad to denote a classic molecular target; actionable specificity requires reference to a defined protein, pathway, or receptor within the parasite. Key clarification: "Leishmania species" is not a molecular target, but an organismal genus. For drug targeting, researchers focus on **proteins or metabolic pathways** unique to Leishmania (e.g., sterol biosynthetic enzymes, kinases, glycoproteins)[8][6]. To match structured molecular target conventions, a specific protein, enzyme, or receptor name within Leishmania should be provided.

Other names

LeishmaniaTrypanosomatid protozoa

Destruction of parasite cell membrane integrity (Amphotericin B); Inhibition of DNA synthesis and metabolic pathways (Methotrexate, Pyrimethamine, miltefosine); Targeting parasite-specific biochemical pathways (sterol biosynthesis, folate metabolism)